A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML.

ABSTRACT:

SUBMITTER: Jonas BA 

PROVIDER: S-EPMC10285270 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature